Loading stock data…
BEAM
$30.23+1.33 (+4.60%)
Market OpenUpdated 12:57 PM EDT
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Beam Therapeutics Inc. in the Healthcare sector is trading at $30.23. The stock is currently 17% below its 52-week high of $36.44, remaining 20.1% above its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why BEAM maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$30.23
Potential Upside
5%
Whystock Fair Value$31.74
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Mean target$51.20+69.4%
Range$26.00 – $80.00
Fundamentals
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogen...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.26B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.19%
Volume
Today's trading volume
668,188
Recent News
Why Beam Therapeutics (BEAM) Is Up 5.3% After TIME100 Spotlight and Vanguard Stake Disclosure
In late April 2026, Beam Therapeutics was highlighted on CNBC’s Mad Money as a speculative, pre-earnings gene-editing player, while a recent Vanguard Capital Management filing disclosed a 5.02% beneficial ownership stake in the company. Beam’s inclusion in TIME’s 2026 list of the 10 Most Influential Health & Life Science Companies, alongside emerging clinical validation for its base-editing therapies, has sharpened investor focus on the real-world potential of its technology platform. We’ll...
Beam Therapeutics’ TIME Honor Puts Base Editing And Valuation In Focus
Beam Therapeutics (NasdaqGS:BEAM) was named one of TIME’s 10 Most Influential Health & Life Science Companies of 2026. The recognition highlights Beam’s progress in base editing gene therapies and its growing role in the biotech sector. For investors tracking gene editing, this recognition puts Beam Therapeutics on a short list of companies seen as shaping the future of genetic medicine. Beam focuses on base editing, a form of gene editing that aims to make precise changes to DNA without...
Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?
Is BEAM a good stock to buy? We came across a bullish thesis on Beam Therapeutics Inc. on r/ValueInvesting by Significant-Pair-275. In this article, we will summarize the bulls’ thesis on BEAM. Beam Therapeutics Inc.’s share was trading at $30.69 as of April 21st. Beam Therapeutics (BEAM) is a clinical-stage gene-editing company developing next-generation base editing therapies designed to make precise, […]
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Ondas Inc is losing a lot of money and added that he would rather have to find something new and different that is distinct, while he doesn't see anything distinct about Ondas. As per recent news, Ondas completed its merger with U.S. defense prime contractor Mistral on April 24 in a $175 million deal, adding programs exceeding $1 billion and expanding direct prime participation across U.S. Department of War programs. Don't Miss: Think Your ‘
Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation”
Beam Therapeutics Inc. (NASDAQ:BEAM) was among the stocks on Jim Cramer’s Mad Money radar as he discussed the recent sell-off in AI-related stocks. A caller asked if the stock is a buy, hold, or “forget about it,” and Cramer replied: Oh, okay. I’ll tell you, Beam is a speculative situation. They do have some formulations. […]